Critical Outcome MOA on COTI-2

Critical Outcome Technologies (TSX-V:COT) for the first time has outlined the specific cellular target and mechanism of action for its lead oncology candidate COTI-2.

“We have now demonstrated through a series of key experiments that the Pleckstrin Homology domain of (the protein) AKT/AKT2 is a selective cellular target for COTI-2,” Critical Outcome president Dr. Wayne Danter said in a statement. Experimental evidence indicates that COTI-2 prevents the activation of AKT/AKT2 and its cancer promoting activities.

The company said it will present this new data to prospective partners, including executives from several major pharmaceutical organizations at BIO Europe next week in Vienna. “This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2.”

Shares of Critical Care have jumped 15 cents to 55 cents Wednesday morning.